Clinical Trials Logo

SARS-CoV-2 clinical trials

View clinical trials related to SARS-CoV-2.

Filter by:

NCT ID: NCT05682638 Not yet recruiting - SARS-CoV-2 Clinical Trials

A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19

Start date: February 2023
Phase: Phase 3
Study type: Interventional

A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Older

NCT ID: NCT05599802 Not yet recruiting - SARS-CoV-2 Clinical Trials

Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants

Start date: February 2023
Phase: Phase 1
Study type: Interventional

An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010)

NCT ID: NCT05586126 Terminated - COVID-19 Clinical Trials

AnaConDa-therapy in COVID-19 Patients

Start date: October 1, 2020
Phase:
Study type: Observational

COVID 19-pneumonia may evolve into respiratory insufficiency for which invasive mechanical ventilation is required. Recently, inhaled anesthetics have become available for sedation of critically ill patients. Based upon recent research, these anesthetics may provide advantages in improvement of P/F ratio in ARDS patients. However, up to now, its effects on COVID-19 pneumonia patients is unknown; therefore, this study was designed as a plan to investigate whether the use of inhaled sevoflurane leads to improvement of oxygenation compared to intravenous sedatives in mechanically ventilated COVID-19 patients

NCT ID: NCT05585632 Recruiting - Influenza Clinical Trials

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Start date: October 14, 2022
Phase: Phase 1
Study type: Interventional

The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.

NCT ID: NCT05584202 Recruiting - SARS-CoV-2 Clinical Trials

Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

BabyCOVE
Start date: September 30, 2022
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.

NCT ID: NCT05550142 Active, not recruiting - SARS-CoV-2 Clinical Trials

A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China

Start date: September 16, 2022
Phase: N/A
Study type: Interventional

This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China.

NCT ID: NCT05549206 Not yet recruiting - SARS-CoV-2 Clinical Trials

A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People

Start date: February 2023
Phase: N/A
Study type: Interventional

This is a cohort study to evaluate safety and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China

NCT ID: NCT05547256 Recruiting - SARS-CoV-2 Clinical Trials

A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China

Start date: September 13, 2022
Phase: N/A
Study type: Interventional

This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants Aged 18 years and over in China

NCT ID: NCT05547243 Recruiting - SARS-CoV-2 Clinical Trials

A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China

Start date: September 26, 2022
Phase: N/A
Study type: Interventional

This is a cohort study to evaluate safety and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants aged 18 years and over in China

NCT ID: NCT05516836 Not yet recruiting - Pain Clinical Trials

Addressing Post-COVID-19 Musculoskeletal Symptoms

Start date: December 20, 2022
Phase: N/A
Study type: Interventional

The purpose of the study will be to evaluate the effect of a rehabilitation program on the improvement of patients with post-COVID-19 musculoskeletal symptoms, as well as to quantify the impact of telemedicine that evaluates the evolution of pain, functionality, and quality of life.